Pall Corp. Signs Agreement with ATMI
News Dec 27, 2013
Pall Corporation has announced that it has entered into a definitive agreement with ATMI, Inc. to acquire the ATMI LifeSciences business for $185 million.
ATMI LifeSciences is a technology leader in the field of single-use bioprocess systems and consumables for the pharmaceutical and biopharmaceutical industries.
The transaction, which is expected to close in Pall’s fiscal third quarter, is subject to certain closing conditions, regulatory approvals and labor-related notifications.
“This acquisition immediately strengthens our offering and broadens our already extensive portfolio of advanced solutions for biopharmaceutical customers,” said Larry Kingsley, Pall Chairman and CEO.
Doug Neugold, ATMI’s Chief Executive Officer, said, “We are very happy to have Pall as the new owner of this business, and believe the fit and their capabilities will accelerate its growth and provide great support to our customers.”
For the balance of fiscal 2014, Pall expects the acquisition to add $20 - $30 million in revenue, be $0.05 - $0.08 dilutive to EPS on a GAAP basis and almost breakeven on a cash EPS basis.
Pall reaffirms its total overall fiscal 2014 guidance for pro forma EPS to be $3.30 - $3.50.
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018